Affimed NV (AFMD) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

AFMD Affimed NV

Watchlist

5.1500
-0.2900-5.33%

Close Jul 19 16:00 ET

5.2200
+0.0700+1.36%

Post 17:55 ET

78.42MMarket Cap-760P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Artiva Biotherapeutics Surges on Trading Debut
Seeking AlphaJul 19 13:16 ET
Cell Therapy Developer Artiva Refiles for a $100M IPO
Seeking AlphaJun 29 10:07 ET
Truist Financial Maintains Affimed NV(AFMD.US) With Buy Rating, Announces Target Price $25
Truist Financial analyst Srikripa Devarakonda maintains $Affimed NV(AFMD.US)$ with a buy rating, and sets the target price at $25.According to TipRanks data, the analyst has a success rate of 0.0% and
moomoo NewsJun 17 22:33 ET · Ratings
Affimed Price Target Raised to $25.00/Share From $15.00 by Laidlaw & Co.
Affimed Price Target Raised to $25.00/Share From $15.00 by Laidlaw & Co.
Dow JonesJun 13 10:34 ET
Affimed Is Maintained at Buy by Laidlaw & Co.
Affimed Is Maintained at Buy by Laidlaw & Co.
Dow JonesJun 13 10:34 ET
Truist Financial Maintains Affimed NV(AFMD.US) With Buy Rating
Truist Financial analyst Srikripa Devarakonda maintains $Affimed NV(AFMD.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 48.9% and a total average return of 5.5% o
moomoo NewsJun 13 07:32 ET · Ratings

Comments

Trytosaveabit

Jun 12 07:05

For you notes!

$Affimed NV(AFMD.US)$ Upcoming Milestones: • Data readout from the 12 patients in cohorts 1 and 2 of the LuminICE-203 (AFM13 combination with AlloNK® cells) study in Q3 2024.
• ORR and PFS data from the 25 patients in the EGFRmut cohort of the AFM24-102 study in Q3 2024.
• ORR and PFS data from the 40 patients in the EGFRwt cohort of the AFM24-102 study in Q4 2024.